Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21438893 | 0.79 | HTT (0.32) | ALDH1A1NPSR1HTTSMN1; SMN2 | |
| SCHEMBL21439236 | 0.79 | PKM (0.33) | ALDH1A1NPSR1HTTSMN1; SMN2 | |
| SCHEMBL21245097 | 0.78 | NUDT1 (0.38) | HTTSMN1; SMN2 | |
| SCHEMBL21438556 | 0.77 | HTT (0.31) | HTTSMN1; SMN2 | |
| SCHEMBL21244926 | 0.76 | MEN1 (0.33) | HTTSMN1; SMN2 | |
| SCHEMBL21438906 | 0.76 | SIGMAR1 (0.31) | HTT | |
| SCHEMBL26667193 | 0.76 | EPHX2 (0.41) | — | |
| SCHEMBL21438610 | 0.74 | L3MBTL1 (0.31) | — | |
| SCHEMBL22392306 | 0.73 | CFTR (0.39) | — | |
| SCHEMBL20239860 | 0.73 | L3MBTL1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008132502-A1 | PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008117050-A1 | PYRAZOLYL-AMINO-SUBSTITUTED PYRAZINES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | WO | disclosed |